medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2008, Number 1

<< Back Next >>

Rev Invest Clin 2008; 60 (1)

Frequency of TS1494del6 polymorphism in colorectal patients from west of Mexico

Gallegos-Arreola MP, Peralta-Leal V, Morgan-Villela G, Puebla-Pérez AM

Language: Spanish
References: 36
Page: 21-30
PDF size: 175.45 Kb.


ABSTRACT

Thymidylate synthase (TYMS) converts dUMP to dTMP, the rate-limiting nucleotide in DNA synthesis. It is also the target for 5-flurouracil, the most common chemotherapy agent for treatment of colorectal cancer (CRC). We designed a case-control study to investigate the frequency of TS 1494del6 polymorphism in patients with CRC and controls from Mexican population. The study consists of 253 patients with CRC and 200 control subjects. Risk of CRC was estimated by use of Odds ratio (95% CI) analysis. The genotype 6bp-/6bp- in CRC patients was 18% (45/253) and in controls was 11% (22/200) with Odds ratio of 1.8 (1-4) with P = 0.059. When stratifying the training groups by age (‹ 50 years), male gender, stage III-IV and presence of metastasis, the genotype 6bp-/6bp- was as risk (p ‹ 0.05). The genotype 6bp-/6bp- in the region untranslated 3´ of TS gene, in the analyzed sample participates in important way in the development of CRC of the Mexican population.


REFERENCES

  1. Mohar A, Frias-Mendivil M, Suchil-Bernal L, et al. Descriptive epidemiology cancer in the National Cancer Institute of Mexico. Salud Pública Mex 1997; 39: 253-358.

  2. http://www.ssa.gob.mx. Secretaría de Salud México. Fecha de último acceso: agosto de 2007.

  3. http://www.ssj.gob.mx. Secretaría de Salud Jalisco. Registro estatal de cáncer en Jalisco. Fecha de último acceso: agosto de 2007.

  4. Kim SA, Lee JH, Park SY, et al. Depressed-type of early colon cancer with extensive lymph node metastasis. Yonsei Med J 2007; 48: 135-8.

  5. Kyoung-Jin S, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate Reductase C677T Polymorphism on Chemosensitivity of Colon and Breast Cancer Cells to 5-Fluorouracil and Methotrexate. J Natl Cancer Inst 2004; 96: 134- 44.

  6. Kralovanszky J, Adleff V, Hitre E, et al. Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine- based adjuvant therapy in colorectal cancer. Magy Onkol 2007; 51: 113-25.

  7. Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A. Germline Polymorphisms may Act as Predictors of Response to Preoperative Chemoradiation in Locally Advanced T3 Rectal Tumors. Dis Colon Rectum 2007 (en prensa).

  8. Hitre E, Budai B, Adleff V, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15: 723-30.

  9. Dotor E, Cuatrecases M, Martinez-Inesita M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 10: 1603-11.

  10. Tsuji T, Hidaka S, Nakagoe T, et al. Polymorphism in the Thymidylate Synthase Promoter Enhancer Region. Is Not an Efficacious Marker for Tumor Sensitivity to 5-Fluorouracil-based Oral Adjuvant Chemotherapy in Colorectal Cancer? Clin Can Res 2003; 9: 3700-04.

  11. Sharp L, Little J. Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review. Am J Epidemiol 2004; 159: 423-43.

  12. Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10: 433-9.

  13. Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9: 1381-5.

  14. Lenz HJ, Zhang W, Zhahedy S, et al. A 6 base-pair deletion in the 30UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors. A possible candidate gene for colorectal cancer risk. Proc Am Assoc Cancer Res 2002; 43: 660.

  15. Ulrich CM, Bigler J, Bostick R, et al. Thymidylate synthase promoter polymorphism, interaction with folate intake and risk of colorectal adenomas. Cancer Res 2002; 62: 3361-4.

  16. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS RNAm levels. Pharmacogenetic 2004; 14: 319-27.

  17. Chen J, Hunter DJ, Stampfer MJ, et al. Polymorphism in the Thymidylate Synthase Promoter Enhancer RegionModifies the Risk and Survival of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958-62.

  18. Ulrich CM, Curtin K, Potter JD. Polymorphisms in the Reduced Folate Carrier, Thymidylate Synthase, or Methionine Synthase and Risk of Colon Cancer. Cancer Epidemiol Biomarkers Prev 2005; 11: 2509-16.

  19. Zhai X, Gao J, Hu Z, et al. Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis. BMC Cancer 2006; 6: 138.

  20. Shi Q, Zhang Z, Neumann A, et al. Case—control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 2005; 26: 649-56.

  21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

  22. Sanguinetti CJ, Dias Neto E, Simpson AJ. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994; 17: 914-21.

  23. Konings EJ, Goldbohm RA, Brants HA, Saris WH, van den Brandt PA. Intake of dietary folate vitamers and risk of colorectal carcinoma: results from The Netherlands Cohort Study. Cancer 2002; 95: 1421-33.

  24. Su LJ, Arab L. Nutritional status of folate and colon cancer risk: evidence from NHANES I epidemiologic follow-up study. Ann Epidemiol 2001; 11: 65-72.

  25. Colorectal cancer. http://www.cchealth.org/health_data/ hospital_council_2007. Fecha de ultimo acceso: agosto de 2007.

  26. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin 2007; 57: 43-66.

  27. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds.). World Health Organization. Cancer incidence in five continents. Vol. VIII. IARC, Scientific Publications Nº 155 (2002).

  28. Alonso A, Moreno S, Valiente A, et al. Genetics mechanisms in the hereditary predisposition to colorectal cancer. Anales Sis San Navarra 2006; 26: 59-76.

  29. Duran O, Gonzalez O, Cisneros L, et al. Experience in the management of colorectal cancer in the Centro Medico Nacional de Occidente (Nacional Medical Center of the West). Cir Gen 2000; 22: 153-8.

  30. Hendon S, DiPalma J. US Practices for colon cancer screening. Keio J Med 2005; 54: 179-83.

  31. Lynch H, Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-32.

  32. Kumar V, Abul K, Nelson F. Patología estructural y funcional. 7a Ed. España: Ed Elsevier; 2005. Acceso en línea.

  33. Zhang J, Cui Y, Luang G, et al. Association of the thymidylate synthase polymorphisms with esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Carcinogenesis 2004; 25: 2479-85.

  34. Surgbarker P. Carcinoma of the colon. Prognosis and operative choice. Curr Prob Surg 1998; 28: 754-826.

  35. Han C, Sheen SM. Obstruction and perforation in colorectal adenocarcinoma: An analysis of prognosis and current trends. Surgery 2000; 127: 370-6.

  36. Aschele C, Debernardis D, Tunesi G, et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000; 6: 4797-802.




2020     |     www.medigraphic.com